B. Valenza

Centre Hospitalier Intercommunal de Fréjus Saint-Raphaël — France

Medicine · Health Sciences

9h-index483citations17works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(9), Breast Cancer Treatment Studies(5), Prostate Cancer Treatment and Research(3), Colorectal Cancer Treatments and Studies(3), Lung Cancer Treatments and Mutations(2)

Publications16 total

727MO FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC): Results of the FFCD 1605 – OPTIPRIME phase II trial
Annals of Oncology·2025· 1 cited
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
Frontiers in Pharmacology·2021· 11 citedOpen Access
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
European Journal of Cancer·2020· 17 cited
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD
Journal of Geriatric Oncology·2020· 21 citedOpen Access
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
The Lancet·2019· 125 cited
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Annals of Oncology·2018· 2 citedOpen Access
Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study
British Journal of Urology·2013· 6 cited
Geographic Tongue Induced by Angiogenesis Inhibitors
The Oncologist·2013· 34 citedOpen Access
Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy
Oncology·2007· 12 cited
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Annals of Oncology·2006· 40 citedOpen Access
AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer
Journal of Clinical Oncology·2005· 5 cited
A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer
Oncology·2004· 31 cited
Weekly Combination of Docetaxel and Vinorelbine in Metastatic Breast Cancer: A Phase I/II Study
Oncology·2004· 8 cited
A phase II of weekly docetaxel for hormone refractory metastatic prostate cancer (HRMPC)
European Urology Supplements·2003· 1 cited
[Brachial fluoroscopically guided implantation of venous port devices in oncology patients].
PubMed·2002· 6 cited
[Simultaneous breast cancer and Hodgkin's disease. A case].
PubMed·1994

Frequent Co-authors

Catherine Delbaldo(4), Laurent Cany(3), Claire Falandry(3), G Lesbats(3), Yves Rinaldi(3), Côme Lepage(3), L. Cals(2), Pascal Piedbois(2), D. Serin(2), Franck Priou(2), P. Laplaige(2), S. Greget(2), Élisabeth Angellier(2), É. Teissier(2), Jean François Berdah(2), Michel Fabbro(2), Cyril Foa(2), Simon Thézenas(2), Philippe Ronchin(2), Frédéric Peyrade(2)